Shen, L., Peng, Z., Li, C., Lu, L., Wang, X., Zhang, J., Zhang, Y., Deng, T., Sun, M., Cai, D., Jin, Y., Zong, H., Ye, F., Xu, H., Zhang, M., Liu, J., Feng, D., Fang, J. (2025). Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba4012